Peptide Tools to Study SARS-CoV-2

About SARS-CoV-2

SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), the causative agent of Covid-19, is responsible for the current pandemic. Developing and monitoring vaccines, therapies and diagnostic tests that are safe, effective, and rapidly deployable is an urgent global health priority.

JPT's Peptide Tools to Study SARS-CoV2

JPT has launched a broad development program to provide access to genome spanning SARS-CoV-2 peptide tools and its different mutation variants for applications such as:

  • SARS-CoV-2 clinical trial immune monitoring
  • SARS-CoV-2 evaluation of cross reactivities
  • SARS-CoV-2 blood and sero test development
  • SARS-CoV-2 T-and B-cell epitope discovery

We have broadened our portfolio of coronavirus related products beyond SARS-CoV-2, including SARS-CoV, MERS-CoV and common cold viruses CoV 229E, OC43, HKU1 and NL63. Have a look!

Cellular Immunity

PepMix™ Peptide Pools for

  • Antigen-specific T-cell stimulation
  • Cellular immune monitoring
  • Vaccine target discovery
  • Blood test development
  • Cross reactivity testing (SARS-CoV-2 vs. SARS, MERS, HCoV 229E, OC43…)
  • Cell therapy development

> Coronavirus PepMixes™
> Customized & Clinical PepMix™ Pools
> Control Pools

Epitope Mapping Peptide Sets (EMPS)

  • Efficient epitope mapping and identification
  • Matrix Pools and individual peptides spanning a whole antigen in one set
  • Minimal sample amount required

> Coronavirus EMPS

Antigen Peptides for

  • Antigen specific T-cell stimulation in T-cell assays (i.e. ELISpot, ICS)
  • Immune monitoring
  • Proliferation assays
  • T-cell expansion

> Coronavirus Antigen Peptides

Humoral Immunity

RepliTope™ Pan Coronavirus for

  • Humoral immune monitoring
  • Antibody epitope discovery
  • Cross reactivity testing (SARS-CoV-2 vs. SARS, MERS, HCoV 229E, OC43…)
  • Seromarker discovery

> RepliTope™ Pan Coronavirus
Customized PepStar™ Peptide Microarrays

Multiwell RepliTopes™ SARS-CoV-2

  • Immune monitoring
  • Antibody epitope discovery
  • Screening individual antigens of SARS-CoV-2 and SARS
  • Seromarker discovery

> RepliTope™ Multiwell Microarrays

Antibody Response Profiling

  • Thousands of peptides spanning the entire SARS-CoV-2 genome using smallest sample volumes
  • Incubation using smallest sample volumes
  • Study of antibody cross-reactivities between SARS-CoV-2 and other corona viruses
  • Verification of peptide binders with a large numbers of samples
  • Transfer of results to ELISA platform for rapid test development

> Antibody Response Profiling

Peptide ELISA

  • Peptide ELISA development and service using SARS-CoV-2 peptides or a combination with other corona viruses
  • ELISA-based validation service of peptide binders identified by using JPT’s peptide microarray platform
  • Collaborative ELISA test development

> Peptide ELISA

Clinical Trial Immune Monitoring & Cell Therapy

Clinical Grade Peptides & PepMix™ Peptide Pools

  • High quality chemically synthesized antigen source for vaccine trial monitoring
  • Ancillary reagents for cellular therapy development
  • Full analytical coverage, stability testing, batch documentation and more

> Clinical Peptides & PepMix™ Peptide Pools™


SpikeMix™ SARS-CoV-2 for

  • Identify SARS CoV-2 antigens from biological samples
  • Mass spectrometry based assays (MRM)
  • Screen 23 proteotypic peptides from SARS-CoV-2

> SpikeMix™ SARS-CoV-2

Spike Mutations in SARS-CoV-2 Variants of Concern covered by PepMix™

References with SARS-CoV-2 Peptide Tools


SARS-CoV-2 Spike Protein Arrested In the Closed State Induces Potent Neutralizing Responses
Carnell et al, bioRxiv (2021)
Robust SARS-CoV-2-specific T Cell Immunity is maintained at 6 Months Following Primary Infection
Zuo et al, Nature (2021)
SARS-CoV-2 Spike Protein Arrested in the Closed State Induces Potent Neutralizing Responses
Oh et al, bioRxiv (2021)
First Report Demonstrating the Safety and Immunogenicity of the SARS-COV-2 BNT162b1 mRNA Vaccine in Younger and Older Chinese Adults: A Randomized, Placebo-Controlled, Observer-Blind Phase I Study
Zhu et al, Research Square (2021)
1IL-2 and IFN-γ are Biomarkers of SARS-CoV-2 Specific Cellular  Response in Whole Blood Stimulation Assays
Pérez-Cabezas et al, medRxiv (2020)
Adaptive Immune Responses to SARS-CoV-2 in Recovered Severe COVID-19 Patients
Olea et al, medRxiv (2020)
Persistent Cellular Immunity to SARS-CoV-2 Infection
Breton et al, bioRxiv (2020)
Deconvoluting the T cell response to SARS-CoV-2: specificity versus chance- and cognate cross-reactivity
Lehmann et al, bioRxiv (2020)
Peptide microarray based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development    
Holenya et a al, medRxiv (2020)
BNT162b2 Induces SARS-CoV-2-Neutralising Antibodies and T cells in Humans
Sahin et al, medRxiv (2020)
Convalescent Plasma Therapy for B-Cell Depleted Patients With Protracted COVID-19 Disease     
Hueso et al, Blood (2020)
Divergent SARS‐CoV‐2‐Specific T and B Cell Responses in Severe but Not Mild COVID‐19 Patients
Oja et al, European Journal of Immunology (2020)
mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents
Rauch et al, bioRxiv (2020)
T Cell and Antibody Responses to SARS-CoV-2: Experience From a French Transplantation and Hemodialysis Center During the COVID-19 Pandemic
Candon et al, Am J Transplant  (2020)
Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without Seroconversion
Gallais et al, Emerg Infect Dis (2020)
A Glimpse Into the Diverse Cellular Immunity Against SARS-CoV-2     
Chang  et al, Research Square (2020)
Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and 2 non-human primates
Kalnin et al, bioRxiv (2020)
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in Older Adults
Anderson et al, NEJM (2020)
Divergent SARS-CoV-2-specific T and B cell Responses in Severe but Not Mild COVID-19
Oja et al, bioRxiv (2020)
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Corbett et al, New England J of Med (2020)
Presence of SARS-CoV-2 reactive T cells in COVID-19 Patients and Healthy Donors
Braun et al, Nature (2020)
Single-shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques
Mercado et al, Nature (2020)
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
Corbett et al, bioRxiv (2020)
Data, Reagents, Assays and Merits of Proteomics for SARS-CoV-2 Research and Testing
Zecha et al, Mol Cell Proteomics (2020)
A Longitudinal Study of Immune Cells in Severe COVID-19 Patients
Payen et al, medRXiv (2020)
SARS-CoV-2-specific T cells Exhibit Unique Features Characterized by Robust Helper Function, Lack of Terminal Differentiation, and High Proliferative Potential
Neidleman et al, bioRxiv (2020)
Generation of SARS-CoV-2 S1 Spike Glycoprotein Putative Antigenic Epitopes in vitro by Intracellular Aminopeptidases
Stamatakis et al bioRxiv (2020)
Self-amplifying RNA SARS-CoV-2 Lipid Nanoparticle Vaccine Candidate Induces High Neutralizing Antibody Titers in Mice
McKay et al, Nature 2020
An mRNA Vaccine Against SARS-CoV-2 — Preliminary Report
Jackson et al, New England J of Med (2020)
SARS‐CoV‐2‐Reactive Interferon‐γ‐producing CD8+ T cells in Patients Hospitalized with Coronavirus Disease 2019
Giminez et al, J Med Vir (2020)
Concurrent Human Antibody and TH1 type T-cell Responses 2 Elicited by a COVID-19 RNA Vaccine
Sahin et al, medRXiv (2020)

Further references



Stay in touch and be the first to receive the latest news!